In knee arthroplasty patients, distal femur BMD at the 15% and 25% regions increased in the abaloparatide group and differed from untreated controls by 4.6% to 7.6% at 6 and 15 months after surgery.
In plain wordsAbaloparatide was linked to greater bone density in two distal femur regions than in untreated controls.
- Peptide
- Abaloparatide (Tymlos)
- Outcome
- IncreaseDistal femur BMD at 15% and 25% ROIs
- Study
n = 58
- Comparator
- Untreated osteopenic controls
- Outcome group
- Bone and joint · Musculoskeletal
- Studied dose
- Dose not stated · Mean 96 (SD 60) days before TKA; follow-up at 6 and 15 months after TKAAs given in this study (human).
Measurements
- Between-group BMD difference
- 4.6 to 7.6%
- 15% and 25% ROIs, 6 and 15 months post-TKA
Source sentences
ABL group distal femur BMD increased at the 15% and 25% ROIs and differed from control by 4.6% to 7.6% (all p < 0.01) at 6 and 15 months post-TKA.
1 context sentence(design, population, supporting numbers)
TKA candidates age ≥55 years were enrolled in this open-label, prospective, observational 18-month study. Those with clinical osteoporosis, defined as lowest T-score ≤ -2.5 or < -1.0 if prior low-trauma fracture, received daily ABL. TKA patients with osteopenia without fracture comprised an u…